Cytosorbents Corporation — FY2012 Form 10-K
Reporting period: Fiscal year ended December 31, 2012; filed April 1, 2013. This is an annual report, not a standalone Q4 filing. The filing does not provide a clear Q4-only financial breakdown.
Business context
CytoSorbents was a development-stage medical-device company developing polymer-based blood-purification products. Its lead product, CytoSorb, had CE Mark approval for use as an extracorporeal cytokine filter and was being commercialized in Germany, Austria and Switzerland. The company reported 32 issued U.S. patents and additional applications pending.
Financial results and liquidity
| Metric | FY2012 | FY2011 |
|---|---|---|
| Total revenue | $1.343 million | $36,000 |
| Product sales | $151,574 | $36,078 |
| Grant income | $1.191 million | $0 |
| Gross profit | $1.024 million | $24,318 |
| Research and development | $2.532 million | $2.888 million |
| Net loss | $3.664 million | $5.482 million |
| Net loss available to common shareholders | $6.175 million | $8.569 million |
| Net cash used in operations | $3.616 million | $3.829 million |
Total revenue rose sharply, primarily because of grant income and initial CytoSorb sales. Gross profit includes grant activity; the filing does not clearly state a product-only gross margin. Lower net loss reflected, among other items, reduced interest expense and a $392,000 tax benefit from selling New Jersey net operating losses. Preferred-stock dividends were $2.511 million in 2012, largely noncash, contributing to the larger loss attributable to common shareholders.
At year-end, cash was $1.729 million, current assets $2.940 million, current liabilities $2.077 million, and working capital approximately $863,000. Current liabilities included $926,225 of convertible notes, net of discount; no long-term notes were reported at year-end. Operating cash use was funded in part by $4.211 million of financing cash flow, and cash increased $543,000 during the year. Management estimated available cash would fund operations into Q3 2013, but said further financing would be needed. The auditor highlighted substantial doubt about the company’s ability to continue as a going concern.
Changes and developments
- Revenue increased from $36,000 to $1.343 million, including $152,000 of product sales and $1.191 million of grant revenue.
- CytoSorb’s German commercial launch began in June 2012; the full sales team was in place by Q4. Cumulative sales from the controlled-market release through year-end were approximately $188,000.
- R&D expense decreased 12.3% to $2.532 million. Legal, financial and consulting costs increased 83.1% to $627,000, and general and administrative expense increased 10.1% to $1.355 million.
- Net interest expense fell 46% to $564,000, mainly due to lower noncash debt-discount amortization.
- Cash rose from $1.187 million to $1.729 million, while total liabilities rose from $1.804 million to $2.077 million. Series B preferred stock was reclassified as temporary equity; the company said this had no impact on net income.
Outlook, risks and unusual items
- Management planned to continue European commercialization, expand sales beyond the initial markets, and conduct additional clinical studies, subject to adequate funding and continued positive results. A German dose-ranging study was underway; U.S. trials and FDA approval remained uncertain. No quantified sales or earnings guidance was provided.
- DARPA awarded a five-year development contract valued at $3.8 million; approximately $1.1 million of grant income was recognized in 2012. The company was finalizing a separate $1 million U.S. Army Phase II SBIR contract. Federal sequestration could delay grant payments.
- The European Sepsis Trial reported a statistically significant 30–50% reduction in key cytokines in 43 electronically randomized patients. Favorable mortality results came from post-hoc subgroups in a small study; the trial was not powered to establish mortality benefit, and larger prospective studies are needed.
- The company had an accumulated deficit of $98.7 million and expected continuing losses. Funding depended on additional capital, including a Lincoln Park Capital facility; equity sales could materially dilute shareholders. In Q1 2013, the company reported raising approximately $450,000 from LPC.
- Series A and B preferred stock carry 10% dividends, with rates that can rise to 20% upon specified defaults. Series B has priority over common stock in liquidation and potential redemption rights. Preferred-stock dividends and conversions, options, warrants and LPC funding create significant potential dilution.
- Management concluded disclosure controls and internal control over financial reporting were ineffective and identified material weaknesses involving audit oversight, public-company accounting expertise, and oversight of the German subsidiary.
- Other risks include uncertain product adoption and reimbursement, regulatory approval and clinical efficacy, manufacturing scale-up, competition, product liability and intellectual-property disputes. The company reported no material pending legal proceeding.
Important facts for investors to verify
- Current cash runway, subsequent financing, and the status and terms of further LPC share sales.
- CytoSorb sales, repeat hospital orders, reimbursement expansion, and commercial progress by country.
- Results and timing of the dose-ranging study and whether larger prospective trials confirm clinical benefit.
- Execution and cash receipts under the DARPA and Army contracts, including any payment delays.
- Fully diluted share count and the impact of preferred-stock dividends, conversions, options, warrants, notes and authorized-share increases.
- Progress remediating the reported material weaknesses and maintaining required CE Mark quality and regulatory compliance.